CytomX Therapeutics Reports Positive Phase 1a Data for CX-904 and Updates on Pipeline Progress

CytomX Therapeutics, Inc. (Nasdaq: CTMX) reports positive Phase 1a data for CX-904 in solid tumors, clearance of first dose cohort for CX-2051 study, and ongoing activities for CX-801 study initiation. The company also achieved $10 million in milestones with Astellas. Dr. Zhen Su joins the Board of Directors. CEO Sean McCarthy expresses optimism about the company’s progress and upcoming data readouts.